

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

### CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date 2 August 2001 (02.08.2001)

**PCT** 

(10) International Publication Number WO 01/55312 A2

				<del></del>		
(51)	International Pa	tent Classification7:	C12N	60/225,214	14 August 2000 (14.08.2000)	US
				60/226,279	18 August 2000 (18.08.2000)	US
(21)	International Ap	plication Number: PCT/US	501/01321	60/226,868	22 August 2000 (22.08.2000)	US
				60/227,182	22 August 2000 (22.08.2000)	US
(22)	loternational Fil	ing Date: 17 January 2001 (17	7.01.2001)	60/226,681	22 August 2000 (22.08.2000)	US
				60/227,009	23 August 2000 (23.08.2000)	US
(20)	Filing Language:		English	60/228,924	30 August 2000 (30.08.2000)	US
(30)	miletianian Tana		F 11.1	60/229,344	1 September 2000 (01.09.2000)	US
(20)	Publication Lang	guage:	English	60/229,343	1 September 2000 (01.09.2000)	US
(20)	Priority Data:			60/229,287	1 September 2000 (01.09.2000)	US
(30)	60/179,065	31 January 2000 (31.01.20	00) US	60/229,345	1 September 2000 (01.09.2000)	US
	60/180,628	4 February 2000 (04.02.20	•	60/229,513	5 September 2000 (05.09.2000)	US
	60/184,664	24 February 2000 (04.02.20		60/229,509	5 September 2000 (05.09.2000)	US
	60/186,350			60/230,438	6 September 2000 (06.09.2000)	US
	60/189.874	2 March 2000 (02.03.20		60/230,437	6 September 2000 (06.09.2000)	US
	60/190,076	16 March 2000 (16.03.20		60/231,413	8 September 2000 (08.09.2000)	US
	60/198,123	17 March 2000 (17.03.20	•	60/232,080	8 September 2000 (08.09.2000)	US
•		18 April 2000 (18.04.20	•	60/231,414	8 September 2000 (08.09.2000)	US
	60/205,515	19 May 2000 (19.05.20	•	60/231,244	8 September 2000 (08.09,2000)	US
	60/209,467	7 June 2000 (07.06.20	•	60/232,081	8 September 2000 (08.09.2000)	US
	60/214,886	28 June 2000 (28.06.20		60/231,242	8 September 2000 (08.09.2000)	US
	60/215,135	30 June 2000 (30.06.20	•	60/231,243	8 September 2000 (08.09.2000)	US
	60/216,647	7 July 2000 (07.07.20		60/231,968	12 September 2000 (12.09.2000)	US
	60/216,880	7 July 2000 (07.07.20		60/232,401	14 September 2000 (14.09.2000)	US
	60/217,487	11 July 2000 (11.07.20	•	60/232,399	14 September 2000 (14.09.2000)	US
	60/217,496	11 July 2000 (11.07.20		60/232,400	14 September 2000 (14.09.2000)	US
	60/218,290	14 July 2000 (14.07.20		60/232,397	14 September 2000 (14.09.2000)	US
	60/220,963	26 July 2000 (26.07.20		60/233,063	14 September 2000 (14.09.2000)	US
	60/220,964 60/225,757	26 July 2000 (26.07.20	,	60/233,064	14 September 2000 (14.09.2000)	US
	60/225,757	14 August 2000 (14.08.20	•	60/233,065	14 September 2000 (14.09.2000)	US
		14 August 2000 (14.08.20		60/232,398	14 September 2000 (14.09.2000)	US
	60/225,447	14 August 2000 (14.08.20		60/234,223	21 September 2000 (21.09.2000)	US
	60/225,267	14 August 2000 (14.08.20	•	60/234,274	21 September 2000 (21.09.2000)	US
	60/225,758	14 August 2000 (14.08.20		60/234,997	25 September 2000 (25.09.2000)	US
	60/225,268	14 August 2000 (14.08.20		60/234,998	25 September 2000 (25.09.2000)	US
	60/224,518	14 August 2000 (14.08.20	•	60/235,484	26 September 2000 (26.09.2000)	US
	60/224,519	14 August 2000 (14.08.20		60/235,834	27 September 2000 (27.09.2000)	US
	60/225,759	14 August 2000 (14.08.20		60/235,836	27 September 2000 (27.09.2000)	US
	60/225,213	14 August 2000 (14.08.20		60/236,369	29 September 2000 (29.09.2000)	US
	60/225,266	14 August 2000 (14.08.20	00) US	•		

[Continued on next page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel fetal tissue related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "fetal tissue antigens", and the use of such fetal tissue antigens for detecting disorders of the fetal tissues, particularly the presence of cancer and cancer metastases. More specifically, isolated fetal tissue associated nucleic acid molecules are provided encoding novel fetal tissue associated polypeptides. Novel fetal tissue polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human fetal tissue associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to fetal tissue and/or proliferating cells, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypetides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

## WO 01/55312 A2

# 

60/236,327	29 September 2000 (29.09.2000)	US	;
60/236,370	29 September 2000 (29.09.2000)	US	i
60/236,368	29 September 2000 (29.09.2000)	US	;
60/236,367	29 September 2000 (29.09.2000)	US	i
60/237,039	2 October 2000 (02.10.2000)	US	,
60/237,038	2 October 2000 (02.10.2000)	US	
60/237,040	2 October 2000 (02.10.2000)	US	
60/237,037	2 October 2000 (02.10.2000)	US	
60/236.802	2 October 2000 (02.10.2000)	US	
60/239,937	13 October 2000 (13.10,2000)	US	
60/239,935	13 October 2000 (13.10.2000)	US	
60/241,785	20 October 2000 (20.10.2000)	US	
60/241,809	20 October 2000 (20.10.2000)	US	
60/240,960	20 October 2000 (20.10.2000)	US	
60/241,787	20 October 2000 (20.10.2000)	US	
60/241,808	20 October 2000 (20.10,2000)	US	
60/241,221	20 October 2000 (20.10.2000)	US	
60/241,786	20 October 2000 (20.10.2000)	US	
60/241,826	20 October 2000 (20.10.2000)	US	
60/244,617	I November 2000 (01.11.2000)	US	
60/246,474	8 November 2000 (08.11.2000)	US	
60/246,532	8 November 2000 (08.11.2000)	US	
60/246,476	8 November 2000 (08.11.2000)	US	
60/246,526	8 November 2000 (08.11.2000)	US	
60/246,527	8 November 2000 (08.11.2000)	US	
60/246,475	8 November 2000 (08.11.2000)	US	
60/246,525	8 November 2000 (08.11.2000)	US	
60/246,477	8 November 2000 (08.11.2000)	US	
60/246,528	8 November 2000 (08.11.2000)	US	
60/246,611	8 November 2000 (08.11.2000)	US	
60/246,610	8 November 2000 (08.11.2000)	US	
60/246,613	8 November 2000 (08.11.2000)	US	
60/246,609	8 November 2000 (08.11.2000)	US	
60/246,478	8 November 2000 (08.11.2000)	US	
60/246,524	8 November 2000 (08.11.2000)	US	
60/246,523	8 November 2000 (08.11.2000)	US	
60/249,299	17 November 2000 (17.11.2000)	US	
60/249.210	17 November 2000 (17.11.2000)	US	
60/249,216	17 November 2000 (17.11.2000)	US	
60/249,217	17 November 2000 (17.11.2000)	US	
60/249,211 60/249,215	17 November 2000 (17.11.2000)	US	
60/249,215	17 November 2000 (17.11.2000)	US	
60/249,218	17 November 2000 (17.11.2000)	US	
60/249,213	17 November 2000 (17.11.2000)	US	
60/249,213	17 November 2000 (17.11.2000)	US	
(0/0 10 00-	17 November 2000 (17.11.2000)	US	
60/249,207 60/249,245	17 November 2000 (17.11.2000)	US	
60/249,243	17 November 2000 (17.11.2000)	US	
60/249,297	17 November 2000 (17.11.2000)	US	
60/249,214	17 November 2000 (17.11.2000)	US	
60/249,264	17 November 2000 (17.11.2000)	US	
60/249,209	17 November 2000 (17.11.2000)	US	
60/249,300	17 November 2000 (17.11.2000)	US	
60/249,265	17 November 2000 (17.11.2000) 17 November 2000 (17.11.2000)	US	
60/250,391	17 November 2000 (17.11.2000) 1 December 2000 (01.12.2000)	US	
60/250,160	1 December 2000 (01.12.2000)	US	
60/256,719	5 December 2000 (05.12.2000)	US	
60/251.030	5 December 2000 (05.12.2000)	US US	
60/251,988	5 December 2000 (05.12.2000)	US	
	- 5000 (UJ.12.2000)	US	

•	
6 December 2000 (06.12,2000)	US
	6 December 2000 (06.12.2000) 8 December 2000 (08.12.2000) 11 December 2000 (11.12.2000) 5 January 2001 (05.01.2001)

- (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Lane, Laytonsville. MD. 20882 (US). BARASH, Steven, C. [US/US]; J/1 Watkins Pond Blvd. #301, Rockville, MD 20850 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (48) Date of publication of this corrected version:

7 September 2001

(15) Information about Correction:

see PCT Gazette No. 36/2001 of 7 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

#### (19) World Intellectual Property Organization International Bureau



# 

#### (43) International Publication Date . 2 August 2001 (02.08.2001)

### (10) International Publication Number WO 01/55312 A3

51)	International Pat	ent Classification <sup>7</sup> :	C07H 2	1/02.	60/225,214	14 August 2000 (14.08.2000)	US
	21/04, C07K 1/00	, 14/00, 17/00			60/226,279	18 August 2000 (18.08.2000)	US
					60/226,868	22 August 2000 (22.08.2000)	US
21)	International Ap	plication Number: P	CT/US01/0	1321	60/227,182	22 August 2000 (22.08.2000)	US
Í					60/226,681	22 August 2000 (22.08.2000)	US
221	International Fili	ng Date: 17 January 20	001717013	2001)	60/227.009	23 August 2000 (23.08.2000)	US
,		ing Duries 17 sumulary 2.		,	60/228,924	30 August 2000 (30.08.2000)	US
251	Filing Language:		C.	iglish	60/229.344	1 September 2000 (01.09,2000)	US
,	rining Language.		E	igusa	60/229,343	I September 2000 (01,09,2000)	US
	Dublined - 1		-	.0.4	60/229,287	1 September 2000 (01.09.2000)	US
.0)	Publication Lang	uage:	En	ıglish	60/229,345	1 September 2000 (01.09.2000)	US
					60/229,513	5 September 2000 (05.09.2000)	US
U)	Priority Data:				60/229,509	5 September 2000 (05.09.2000)	US
	60/179,065	31 January 2000 (3)		US	60/230,438	6 September 2000 (06.09,2000)	US
	60/180.628	4 February 2000 (04		US	60/230,437	6 September 2000 (06.09,2000)	US
	60/184,664	24 February 2000 (24		US	60/231,413	8 September 2000 (08.09,2000)	US
	60/186.350	2 March 2000 (02		US	60/232,080	8 September 2000 (08.09.2000)	US
	60/189,874	16 March 2000 (10		US	60/231,414	8 September 2000 (08.09.2000)	US
	60/190,076	17 March 2000 (11	•	US	60/231,244	8 September 2000 (08.09.2000)	US
	60/198,123	18 April 2000 (11		US	60/232,081	8 September 2000 (08.09,2000)	US
	60/205,515	19 May 2000 (19		US	60/231,242	8 September 2000 (08.09.2000)	US
	60/209,467	7 June 2000 (01		US	60/231,243	8 September 2000 (08.09,2000)	US
	60/214,886	28 June 2000 (28		US	60/231,968	12 September 2000 (12.09.2000)	US
	60/215,135	30 June 2000 (30		US	60/232,401	14 September 2000 (14.09.2000)	US
	60/216,647	7 July 2000 (0°		US	60/232,399	14 September 2000 (14.09.2000)	US
	60/216.880	7 July 2000 (0°	•	US	60/232,400	14 September 2000 (14.09.2000)	US
	60/217,487	11 July 2000 (1	-	US	60/232,397	14 September 2000 (14.09.2000)	US
	60/217,496	11 July 2000 (1		US	60/233,063	14 September 2000 (14.09.2000)	US
	60/218.290	14 July 2000 (14		US	60/233,064	14 September 2000 (14.09.2000)	US
	60/220,963	26 July 2000 (20		US	60/233,065	14 September 2000 (14,09,200)	US
	60/220,964	26 July 2000 (20	•	US	60/232,398	14 September 2000 (14.09.2000)	US
	60/225,757	14 August 2000 (14		US	60/234,223	21 September 2000 (21,09,2000)	US
	60/225,270	14 August 2000 (14		US	60/234,274	21 September 2000 (21.09.2000)	US
	60/225,447	14 August 2000 (14	•	US	60/234,997	25 September 2000 (25,09,2000)	US
	60/225,267	14 August 2000 (14	4.08.2000)	US	60/234,998	25 September 2000 (25.09.2000)	US
	60/225,758	14 August 2000 (14		US	60/235,484	26 September 2000 (26.09.2000)	US
	60/225,268	14 August 2000) (14	-	US	60/235,834	27 September 2000 (27.09.2000)	US
	60/224,518	14 August 2000 (14	-	US	60/235,836	27 September 2000 (27.09.2000)	US
	60/224.519	14 August 2000 (14	•	US	60/236,369	29 September 2000 (29.09.2000)	US
	60/225,759	14 August 2000 (14	-	US	60/236,327	29 September 2000 (29,09,2000)	US
	60/225,213	14 August 2000 (14	4.08.2000)	US	60/236,370	29 September 2000 (29.09.2000)	US
	60/225,266	14 August 2000 (14		US	00/230.370	27 SCHCHRC 2000 (29.09.2000)	

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel fetal tissue related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "fetal tissue antigens", and the use of such fetal tissue antigens for detecting disorders of the fetal tissues, particularly the presence of cancer and cancer metastases. More specifically, isolated fetal tissue associated nucleic acid molecules are provided encoding novel fetal tissue associated polypeptides. Novel fetal tissue polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human fetal tissue associated polynucleotides and/or polypoptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to fetal tissue and/or proliferating cells, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypetides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

60/236,367	29 September 2000 (29,09,2000)	US
60/237,039	2 October 2000 (02, 10, 2000)	US
60/237,038	2 October 2000 (02, 10, 2000)	US
60/237,040	2 October 2000 (02.10.2000)	US
60/237.037	2 October 2000 (02.10.2000)	US
60/236,802	2 October 2000 (02.10.2000)	US
60/239.937	13 October 2000 (13.10.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US
60/241,808	20 October 2000 (20.10.2000)	US
60/241,221	20 October 2000 (20.10.2000)	US
60/241.786	20 October 2000 (20.10.2000)	US
60/241,826	20 October 2000 (20,10,2000)	US
60/244,617	I November 2000 (01.11.2000)	US
60/246.474	8 November 2000 (08.11.2000)	US
60/246,532	8 November 2000 (08.11.2000)	US
60/246,476	8 November 2000 (08.11.2000)	US
60/246,526	8 November 2000 (08.11.2000)	US
60/246,527	8 November 2000 (08.11.2000)	US
60/246,475	8 November 2000 (08.11,2000)	US
60/246,525	8 November 2000 (08.11.2000)	US
60/246;477	8 November 2000 (08.11.2000)	US
60/246,528	8 November 2000 (08.11.2000)	US
60/246,611	8 November 2000 (08.11.2000)	US
60/246,610	8 November 2000 (08.11.2000)	US
60/246,613	8 November 2000 (08.11.2000)	US
60/246,609	8 November 2000 (08.11.2000)	US
60/246,478	8 November 2000 (08.11.2000)	US
60/246,524	8 November 2000 (08.11.2000)	US
60/246,523	8 November 2000 (08.11,2000)	US
60/249,299 60/249,210	17 November 2000 (17.11.2000)	US
60/249,210	17 November 2000 (17.11.2000)	US
60/249,216	17 November 2000 (17.11.2000)	US
60/249,217	17 November 2000 (17.11.2000)	US
	17 November 2000 (17.11.2000)	US
60/249,215 60/249,218	17 November 2000 (17.11.2000)	US
60/249,218	17 November 2000 (17.11.2000)	US
60/249,213	17 November 2000 (17.11.2000)	US
60/249,213	17 November 2000 (17.11.2000)	US
60/249,217	17 November 2000 (17.11.2000)	US
60/249,245	17 November 2000 (17.11,2000)	US
60/249,244	17 November 2000 (17.11,2000)	US
60/249,247	17 November 2000 (17.11,2000)	US
60/249,214	17 November 2000 (17.11.2000)	US
60/249,264	17 November 2000 (17.11.2000)	US
60/249,209	17 November 2000 (17.11.2000)	US
60/249,300	17 November 2000 (17.11.2000)	US
60/249,265	17 November 2000 (17.11.2000)	US
60/250,391	17 November 2000 (17.11.2000)	US
60/250,160	December 2000 (01.12.2000)	US
60/256,719	1 December 2000 (01.12.2000)	US
60/251,030	5 December 2000 (05.12.2000) 5 December 2000 (05.12.2000)	US
50/251,988	5 December 2000 (05.12.2000) 5 December 2000 (05.12.2000)	US
50/251,479	6 December 2000 (05.12.2000)	US
	6 December 2000 (06.12.2000)	US

60/251,869	8 December 2000 (08,12,2000)	US
60/251,856	8 December 2000 (08.12.2000)	US
60/251,868	8 December 2000 (08.12,2000)	US
60/251,990	8 December 2000 (08.12.2000)	US
60/251,989	8 December 2000 (08.12.2000)	US
60/254,097	11 December 2000 (11.12.2000)	US
60/259,678	5 January 2001 (05.01.2001)	US

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]: 9410 Key West Avenue, Rockville, MI) 20850 (US).

#### (72) Inventors; and

- (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]: 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). BARASH, Steven, C. [US/US]; 111 Watkins Pond Blvd. #301, Rockville, MD 20850 (US). RUBEN, Steven, M. [US/US]: 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: HOOVER, Kenley, K. et al.: Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE. AG. AL. AM. AT. AU. AZ. BA. BB. BG. BR. BY. BZ. CA. CH. CN. CR. CU. CZ. DE. DK. DM. DZ. EE. ES. FI. GB. GD. GE. GH. GM. HR. HU. ID. IL. IN. IS. JP. KE. KG. KP. KR. KZ. LC. LK. LR. LS. LT. LU. LV. MA. MD. MG. MK. MN. MW. MX. MZ. NO. NZ. PL. PT. RO. RU. SD. SE. SG. SI. SK. SL. TJ. TM. TR. TT. TZ. UA. UG. US. UZ. VN. YU. ZA. ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 14 March 2002
- (15) Information about Correction:

**Previous Correction:** 

see PCT Gazette No. 36/2001 of 7 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Internat d application No. PCT/US01/01321

A. CLASSIFICATION OF SUBJ	ECT MATTER						
IPC(7) : C07H 21/02, 21/04;	CO7K 1/00, 14/00, 17/0	XX					
US CL : 536/23.1, 23.4; 530	7350						
According to International Patent Class	ification (IPC) or to both	national c	lassification and IPC				
B. FIELDS SEARCHED			The state of the s				
Minimum documentation searched (clas	sification system follows	ed by class	ification symbole)				
U.S.: 536/23.1; 530/350	The second second second	ou ny class.	meation sympost				
Dogumentation							
Documentation searched other than min	imum documentation to (	the extent t	hat such documents are included	led in the fields searched			
Electronic data base consultant during at				<del></del>			
Electronic data base consulted during the	ie international search (n	ame of data	a base and, where practicable,	search terms used)			
GeneBank, EMBL, Geneseq, EST, Issu	ed Patents, SPTREMBL	, SwissPro	t, PIR				
C. DOCUMENTS CONSIDERED	TO BE RELEVANT						
Category * Citation of document	with indication, where	"Boronsint	e, of the relevant passages				
A US 5994119 A (DIETZ)	30 NOVEMBED 1000	appropriate	o, of the felevant passages	Relevant to claim No.			
(5)(5)	··· HOTEMBER 1999, \$	בב אבע וח	NU:3.	1			
A US 5,700,674 A (KOYA)	MA et al 123 DECEMBI	CD 1007 .	CEO ID NO I				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	or all, and DECEMBE	UK 1997, S	see sey in MO:1.	1			
l							
1							
				1			
· ·							
	•						
ļ							
	•						
Further documents are listed in the				<u> </u>			
			See patent family annex.				
Special categories of cited documents:		-T-	later document published after the int	ernational filing date or priority			
A" document defining the general state of the art	which is not considered to be		date and not in conflict with the appli	cation but cited to understand the			
of particular relevance			principle or theory underlying the inv	ention			
E" eartier application or patent published on or at	iler the international filling date	-X-	document of particular relevance; the	claimed invention cannot be			
			considered novel or cannot be consider when the document is taken alone	ered to involve an inventive step			
L" document which may throw doubts on priority establish the publication date of another citation	claums) or which is cited to		•				
specified)		"Y"	document of particular relevance; the considered to involve an inventive ste	claimed invention cannot be			
O" document referring to an oral disclosure, use,	ethibition or other		combined with one or more other suci	h documents, such combination			
			being obvious to a person skilled in th	e art			
P" document published prior to the international f priority date claimed	iling date but later than the	<b>"&amp;"</b>	document member of the same patent	family			
Date of the actual completion of the inter	mational search	Date of n	nailing of the international sea	rch report			
			1 1 1 1	acti report			
6 July 2001			14 AUG 2001	)			
Jame and mailing address of the ISA/US  Commissioner of Patents and Trademarks		Authorize	ed officer	(NX			
Box PCT	j	Teresa S	trzelecka TFI	ERY J. DEY   LAT			
Washington, D.C. 20231	Washington D.C. 2001						
			DADALEC	AL SPECIALISMY /			
acsimile No. (703)305-3230 rm PCT/ISA/210 (second sheet) (July 1		Telephon	e No. (703) 308-0106	GAL SPECIAL)STA			

A PROGRAMMENT 1

International application No.

PCT/US01/01321

# BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees

1. Groups 1-886, claim(s) 1-10, 14, 15 and 21, all in part, drawn to an isolated polynucleotide of SEQ ID NO X encoding a peptide of SEQ ID NO NO: Y, wherein X and Y are values that correlate to those listed in Table 1A, and correspond to one of the cDNA Clone Ids, respectively. For example, 911.

If group I is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein X is 11 and Y is

If group 2 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein X is 12 and Y is 912.

- 2. Groups 887-1772, claim(s) 11, 12, 16 and 23, all in part, each group directed to a polypeptide of SEQ ID NO; Y, wherein Y correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example, If group 887 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein Y is 911. If group 888 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein Y is 912.
- 3. Groups 1773-2658, claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example, If group 1773 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein Y is 911. If group 1774 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein Y is 912.
- 4. Groups 2659-3544, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example,

If group 2659 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein X is 11. If group 2660 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein X is 12.

5. Groups 3545-4430, claims 18 and 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example,

If group 3545 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein X is 11. If group 3546 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein X is 12.

6. Groups 4431-5316, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example,

If group 4431 is elected, this correlates to Gene no 1, cDNA clone ID HEZAC66 of Table 1A, wherein Y is 911. If group 44322 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein Y is 912.

7. Groups 5317-6202, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1A, and corresponds to core of the cDNA Clone IDs, respectively. For example,

If group 5317 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1A, wherein X is 11. If group 5318 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein X is 12.

International ar "ication No.

PCT/US01/01321

8. Groups 6203-7088, claim 24, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1A, and corresponds to one of the cDNA Clone IDs, respectively. For example,

If group 6203 is elected, this correlates to Gene no 1, cDNA clone ID HE2AC66 of Table 1, wherein Y is 911. If group 6204 is elected, this correlates to Gene No 2, cDNA clone ID HE2A012, wherein Y is 912.

The inventions listed as Groups 1-7088 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each invention are unrelated, each to each other. Where, for example, claim 1, items (e) through (f) do not require a polynucleotide of any degree of specificity to a sequence, it is apparent that Lindeskog et al. (1999, Virology Vol 258(2) 441-450) discloses a DNA encoding a polypeptide wherein said DNA renders claim 1, among the other, not novel. Thus the technical feature of the polynucleotide sequence is not special and the groups are not so linked under PCT Rule 13.1. Additionally the claimed methods produce different products and/or different results which are not coextensive and which do not share the same technical feature.

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/US01/01321

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claim Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claim Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule  6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 (in part), SEQ ID NO:11
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

### CORRECTED VERSION

#### (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 2 August 2001 (02.08.2001)

**PCT** 

(10) International Publication Number WO 01/55312 A2

_						
(51)	International Pa	tent Classification7:	C12N	60/225,214	14 August 2000 (14.08.2000)	US
				60/226,279	18 August 2000 (18.08.2000)	US
(21)	International Ap	plication Number: PCT/US01	/01321	60/226,868	22 August 2000 (22.08.2000)	US
(22)	B			60/227,182	22 August 2000 (22.08.2000)	US
(22)	International Fil	ing Date: 17 January 2001 (17.01	.2001)	60/226,681	22 August 2000 (22.08.2000)	US
(3E)	Filing Language:			60/227,009	23 August 2000 (23.08.2000)	US
(23)	ring Lauguage	. I	English	60/228,924	30 August 2000 (30.08.2000)	US
(26)	Publication Lang	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	7111	60/229,344	1 September 2000 (01.09.2000)	US
(20)	r ublication Lang	guage:	English	60/229,343	1 September 2000 (01.09.2000)	US
(30)	Priority Data:			60/229,287	1 September 2000 (01.09.2000)	US
(50)	60/179,065	31 January 2000 (31.01.2000)	US	60/229,345	1 September 2000 (01.09.2000)	US
	60/180,628	4 February 2000 (04.02.2000)		60/229,513	5 September 2000 (05.09.2000)	US
	60/184,664	24 February 2000 (24.02.2000)		60/229,509	5 September 2000 (05.09.2000)	US
	60/186,350	2 March 2000 (02.03.2000)		60/230,438	6 September 2000 (06.09.2000)	US
	60/189,874	16 March 2000 (16.03.2000)		60/230,437	6 September 2000 (06.09.2000)	US
	60/190,076	17 March 2000 (17.03.2000)		60/231,413	8 September 2000 (08.09.2000)	US
	60/198,123	18 April 2000 (17.03.2000)		60/232,080	8 September 2000 (08.09.2000)	US
	60/205,515	19 May 2000 (19.05.2000)		60/231,414	8 September 2000 (08.09.2000)	US
	60/209,467	7 June 2000 (17.05.2000)		60/231,244	8 September 2000 (08.09.2000)	US
	60/214,886	28 June 2000 (28.06.2000)		60/232,081	8 September 2000 (08.09.2000)	US
	60/215,135	30 June 2000 (30.06.2000)		60/231,242	8 September 2000 (08.09.2000)	US
	60/216,647	7 July 2000 (07.07.2000)		60/231,243	8 September 2000 (08.09.2000)	US
	60/216,880	7 July 2000 (07.07.2000)		60/231,968	12 September 2000 (12.09.2000)	US
	60/217,487	11 July 2000 (07.07.2000)		60/232,401	14 September 2000 (14.09.2000)	US
	60/217,496			60/232,399	14 September 2000 (14.09,2000)	US
	60/218,290	11 July 2000 (11.07.2000) 14 July 2000 (14.07.2000)		60/232,400	14 September 2000 (14.09.2000)	US
	60/220,963			60/232,397	14 September 2000 (14.09,2000)	US
	60/220,963	26 July 2000 (26.07.2000)		60/233,063	14 September 2000 (14.09,2000)	US
	60/225,757	26 July 2000 (26.07.2000)		60/233,064	14 September 2000 (14.09,2000)	US
	60/225,737	14 August 2000 (14.08.2000)		60/233,065	14 September 2000 (14.09.2000)	US
	60/225,447	14 August 2000 (14.08.2000)		60/232,398	14 September 2000 (14.09.2000)	US
	•	14 August 2000 (14.08.2000)	US	60/234,223	21 September 2000 (21.09.2000)	US
	60/225,267	14 August 2000 (14.08.2000)		60/234,274	21 September 2000 (21.09.2000)	US
	60/225,758	14 August 2000 (14.08.2000)		60/234,997	25 September 2000 (25.09.2000)	US
	60/225,268	14 August 2000 (14.08.2000)		60/234,998	25 September 2000 (25.09.2000)	US
	60/224,518	14 August 2000 (14.08.2000)	US	60/235,484	26 September 2000 (26.09.2000)	US
	60/224,519	14 August 2000 (14.08.2000)		60/235,834	27 September 2000 (27.09.2000)	US
	60/225,759	14 August 2000 (14.08.2000)		60/235,836	27 September 2000 (27.09.2000)	US
	60/225,213	14 August 2000 (14.08.2000)	US	60/236,369	29 September 2000 (29.09.2000)	US
	60/225,266	14 August 2000 (14.08.2000)	US			

[Continued on next page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel fetal tissue related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "fetal tissue antigens", and the use of such fetal tissue antigens for detecting disorders of the fetal tissues, particularly the presence of cancer and cancer metastases. More specifically, isolated fetal tissue associated nucleic acid molecules are provided encoding novel fetal tissue associated polypeptides. Novel fetal tissue polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human fetal tissue associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to fetal tissue and/or proliferating cells, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypetides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

60/236,327	29 September 2000 (29.09.2000)	US
60/236,370	29 September 2000 (29.09.2000)	US
60/236,368	29 September 2000 (29.09.2000)	US
60/236,367	29 September 2000 (29.09.2000)	US
60/237,039	2 October 2000 (02.10.2000)	US
60/237,038	2 October 2000 (02.10.2000)	US
60/237,040	2 October 2000 (02.10.2000)	US
60/237,037	2 October 2000 (02.10.2000)	US
60/236.802	2 October 2000 (02.10.2000)	US
60/239,937	13 October 2000 (13.10.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US
60/241,808	20 October 2000 (20.10.2000)	US
60/241,221	20 October 2000 (20.10.2000)	US
60/241,786	20 October 2000 (20.10.2000)	US
60/241,826	20 October 2000 (20.10.2000)	US
60/244,617	1 November 2000 (01.11.2000)	US
60/246,474	8 November 2000 (08.11.2000)	. US
60/246,532	8 November 2000 (08.11.2000)	US
60/246,476	8 November 2000 (08.11.2000)	US
60/246,526	8 November 2000 (08.11.2000)	US
60/246,527	8 November 2000 (08.11.2000)	US
60/246,475	8 November 2000 (08.11.2000)	US
60/246,525	8 November 2000 (08.11.2000)	US
60/246,477	8 November 2000 (08.11.2000)	US
60/246,528	8 November 2000 (08.11.2000)	US
60/246,611	8 November 2000 (08.11.2000)	US
60/246,610	8 November 2000 (08.11.2000)	US
60/246,613	8 November 2000 (08.11.2000)	US
60/246,609	8 November 2000 (08.11.2000)	US
60/246,478	8 November 2000 (08.11.2000)	US
60/246,524	8 November 2000 (08.11.2000)	US
60/246,523	8 November 2000 (08.11.2000)	US
60/249,299	17 November 2000 (17.11.2000)	US
60/249.210	17 November 2000 (17.11.2000)	US
60/249,216	17 November 2000 (17.11.2000)	US
60/249,217	17 November 2000 (17.11.2000)	US
60/249,211	17 November 2000 (17.11.2000)	US
60/249,215	17 November 2000 (17.11.2000)	US
60/249,218	17 November 2000 (17.11.2000)	US
60/249,208	17 November 2000 (17.11.2000)	US
60/249,213	17 November 2000 (17.11.2000)	US
60/249,212	17 November 2000 (17.11.2000)	US
60/249,207	17 November 2000 (17.11.2000)	US
60/249,245	17 November 2000 (17.11.2000)	US
60/249,244	17 November 2000 (17.11.2000)	US
60/249,297	17 November 2000 (17.11.2000)	US
60/249,214	17 November 2000 (17.11.2000)	US
60/249,264	17 November 2000 (17.11.2000)	US
60/249,209	17 November 2000 (17.11.2000)	US
60/249,300	17 November 2000 (17.11.2000)	US
60/249,265	17 November 2000 (17.11.2000)	US
60/250,391	1 December 2000 (01.12.2000)	US
60/250,160	1 December 2000 (01.12.2000)	US
60/256,719	5 December 2000 (05.12.2000)	US
60/251,030	5 December 2000 (05.12.2000)	US
60/251,988	5 December 2000 (05.12.2000)	US

60/251,479	6 December 2000 (06.12.2000)	US
60/251,869	8 December 2000 (08.12.2000)	US
60/251,856	8 December 2000 (08.12.2000)	US
60/251,868	8 December 2000 (08.12,2000)	US
60/251,990	8 December 2000 (08.12.2000)	US
60/251,989	8 December 2000 (08.12.2000)	US
60/254,097	11 December 2000 (11.12.2000)	US
60/259,678	5 January 2001 (05.01.2001)	US

- (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). BARASH, Steven, C. [US/US]; 111 Watkins Pond Blvd. #301, Rockville, MD 20850 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (48) Date of publication of this corrected version:

7 September 2001

(15) Information about Correction: see PCT Gazette No. 36/2001 of 7 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.